1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

 
• By Alaric DeArment

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

AstraZeneca and Merck are closer to snagging a first-line prostate cancer label for Lynparza • Source: Shutterstock

AstraZeneca plc and Merck & Co., Inc.’s Lynparza (olaparib) has reinforced is lead among PARP inhibitors for prostate cancer with the publication of data from the Phase III PROpel trial showing the drug, combined with Johnson & Johnson’s Zytiga (abiraterone) and prednisone, resulted in lower risk of disease progression or death in first-line patients, irrespective of homologous recombination repair (HRR) mutation status.

Consequently, Lynparza stands to potentially gain access to a significantly larger share of the prostate cancer market, given both the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

More from Therapy Areas

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.